Posted by Michael Wonder on 24 Oct 2023
Bristol Myers Squibb announces US FDA breakthrough therapy designation for investigational LPA1 antagonist for progressive pulmonary fibrosis
24 October 2023 - Designation is based on results from the progressive pulmonary fibrosis cohort of the Phase 2 study assessing the safety and efficacy of BMS-986278 treatment versus placebo
Bristol Myers Squibb today announced that the US FDA has granted breakthrough therapy designation for BMS-986278, a potential first in class, oral, lysophosphatidic acid receptor 1 antagonist, for the treatment of progressive pulmonary fibrosis, a devastating, life-threatening illness.
In addition to this breakthrough therapy designation for progressive pulmonary fibrosis, the US FDA has also previously granted BMS-986278 fast track designation and orphan drug designation for the treatment of idiopathic pulmonary fibrosis.
